Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
截至2024年3月31日，Cellectar Biosciences的現金及現金等價物爲4000萬美元，預計將爲2024年第四季度提供現金流
Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
截至2024年3月31日，Cellectar Biosciences的現金及現金等價物爲4000萬美元，預計將爲2024年第四季度提供現金流
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。